Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 7/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16992560 | 1.00 | CHRM4 (0.53) | CHRM4CHRM2CHRM1TP53TDP1 | |
| SCHEMBL16992382 | 0.95 | CHRM4 (0.53) | CHRM4CHRM2CHRM1TP53TDP1 | |
| SCHEMBL16992516 | 0.95 | CHRM4 (0.53) | CHRM4CHRM2CHRM1TP53TDP1 | |
| SCHEMBL16992453 | 0.95 | CHRM4 (0.53) | CHRM4CHRM2CHRM1TP53TDP1 | |
| SCHEMBL20292064 | 0.94 | CHRM4 (0.47) | CHRM4CHRM2CHRM1TP53TDP1 | |
| SCHEMBL16992364 | 0.94 | CHRM4 (0.52) | CHRM4CHRM2CHRM1TP53TDP1 | |
| SCHEMBL17001974 | 0.93 | CHRM4 (0.48) | CHRM4CHRM2CHRM1TP53TDP1 | |
| SCHEMBL16992497 | 0.93 | CHRM4 (0.50) | CHRM4CHRM2CHRM1TP53TDP1 | |
| SCHEMBL17001976 | 0.93 | CHRM4 (0.50) | CHRM4CHRM2CHRM1TP53TDP1 | |
| SCHEMBL16992172 | 0.93 | CHRM4 (0.48) | CHRM4CHRM2CHRM1TP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | CHRM4 4/4885CHRM2 2/4885CHRM1 1/4885 |
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | CHRM1, CHRM2, CHRM5 | CHRM4 4/4885CHRM2 2/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.